What is the Inovio Pharmaceuticals, Inc. stock price forecast?

Inovio Pharmaceuticals, Inc. is currently trading at $1.11. View real-time AI analysis on Alpha Lenz.

What is Inovio Pharmaceuticals, Inc. insider trading activity?

View the latest insider trading data for Inovio Pharmaceuticals, Inc. on Alpha Lenz.

What is Inovio Pharmaceuticals, Inc.'s P/E ratio?

Inovio Pharmaceuticals, Inc.'s P/E ratio is -0.6.

Inovio Pharmaceuticals, Inc.

NASDAQ · INO

$1.11+0.01(+0.91%)Pre-market

Ask about Inovio Pharmaceuticals, Inc.'s future dividend policy...

Alpha Chat Insight

“Inovio Pharmaceuticals, Inc. trades at a P/E of -0.6 (undervalued) with modest ROE of -183.5%.”

Ask for details →

Company Overview

Inovio Pharmaceuticals, Inc. is a biotechnology company primarily focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio is dedicated to attempting groundbreaking work in addressing infectious diseases, cancer, and diseases where treatment options are limited. Inovio utilizes its proprietary DNA medicine platform to potentially develop immunotherapies that are precisely targeted to stimulate robust immune responses in the human body. The company is notable within the healthcare sector for its innovative approach to preventive and therapeutic solutions. Its portfolio includes ongoing developments in vaccines targeting broad public health concerns, such as human papillomavirus (HPV)-related diseases and specific cancers. Inovio Pharmaceuticals plays a significant role in the biotechnology landscape by striving to produce novel treatments that may improve vaccine efficacy and broaden the scope of immunotherapy applications, positioning itself as a pivotal player in advancing medical treatments through genetic medicine.

CEODr. Jacqueline E. Shea Ph.D.

Websitehttps://www.inovio.com

SectorHealthcare

IndustryBiotechnology

Employees134

Company Statistics

FY 2025

Profile

$52.04MMarket Cap

$65.34KRevenue

0.00Shares Out

134Employees

Margins

N/AGross

-127886.82%EBITDA

-132871.32%Operating

-130000.00%Pre-Tax

-130000.00%Net

Valuation

-0.61P/E

2.16P/B

796.47EV/Sales

-0.21EV/EBITDA

-0.59P/FCF

Growth (CAGR)

-81.47%Rev 3Yr

-61.18%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-90.61%ROA

-183.47%ROE

-90.61%ROIC

Financial Health

$44.27MCash & Cash Equivalents

$5.94MNet Debt

208.39%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Inovio Pharmaceuticals, Inc. trades at a P/E of -0.6 (undervalued) with modest ROE of -183.5%.”

Ask for details →

Frequently Asked Questions

Inovio Pharmaceuticals, Inc. (ticker: INO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 134 employees. Market cap is $52M.

The current price is $1.11 with a P/E ratio of -0.61x and P/B of 2.16x.

ROE is -183.47% and operating margin is -132871.32%. Annual revenue is $65,343.